Tonix Pharmaceuticals has announced the offering of 10,766,666 shares of common stock, accompanied by Series E Warrants to purchase up to 14,666,666 shares of common stock, and Pre-Funded Warrants to purchase up to 3,900,000 shares of common stock. The offering is on a 'reasonable best efforts' basis, with a combined public offering price per share of Common Stock and accompanying Warrants at $0.30. The Series E Warrants have an exercise price of $0.33 per share, exercisable six months from issuance and expiring five and a half years from the date of issuance. The Pre-Funded Warrants, exercisable for one share of Common Stock at $0.0001 per share, are immediately exercisable and will expire when exercised in full. The offering also includes up to 18,566,666 shares of...Show More

Tonix Pharmaceuticals has announced the offering of 10,766,666 shares of common stock, accompanied by Series E Warrants to purchase up to 14,666,666 shares of common stock, and Pre-Funded Warrants to purchase up to 3,900,000 shares of common stock. The offering is on a 'reasonable best efforts' basis, with a combined public offering price per share of Common Stock and accompanying Warrants at $0.30. The Series E Warrants have an exercise price of $0.33 per share, exercisable six months from issuance and expiring five and a half years from the date of issuance. The Pre-Funded Warrants, exercisable for one share of Common Stock at $0.0001 per share, are immediately exercisable and will expire when exercised in full. The offering also includes up to 18,566,666 shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants and Series E Warrants. The securities will be sold in a single closing, with no minimum number of securities or minimum aggregate amount of proceeds required for the offering to close. Proceeds from the sale will be available for immediate use by Tonix Pharmaceuticals, despite uncertainty about the ability to effectively implement their business plan. The offering will terminate no later than April 15, 2024, unless completed sooner or terminated by the company. Tonix Pharmaceuticals' Common Stock is listed on Nasdaq under the symbol 'TNXP.' The closing sale price of the Common Stock on March 27, 2024, was $0.3269 per share. There is no established public trading market for the Series E Warrants or Pre-Funded Warrants, and no market is expected to develop. Investing in the securities involves a high degree of risk. A.G.P./Alliance Global Partners LLC is acting as the placement agent for the offering, with a fee based on the aggregate proceeds raised. The securities are expected to be delivered on or about April 1, 2024.